Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Xencor Inc (NASDAQ:XNCR)

18.94
Delayed Data
As of 3:59pm ET
 +0.38 / +2.05%
Today’s Change
9.89
Today|||52-Week Range
24.07
+29.55%
Year-to-Date
Should You Buy Xencor (XNCR) Ahead of Earnings?
Jul 28 / Zacks.com - Paid Partner Content
Novartis (NVS) Tops Q2 Earnings & Sales, Expenses to Grow
Jul 20 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close18.56
Today’s open18.77
Day’s range18.55 - 19.19
Volume342,965
Average volume (3 months)258,376
Market cap$765.2M
Dividend yield--
Data as of 3:59pm ET, 07/29/2016

Growth & Valuation

Earnings growth (last year)+13.46%
Earnings growth (this year)-62.55%
Earnings growth (next 5 years)--
Revenue growth (last year)+191.62%
P/E ratioNM
Price/Sales20.55
Price/Book4.69

Competitors

 Today’s
change
Today’s
% change
AMPHAmphastar Pharmaceut...-0.09-0.55%
SGYPSynergy Pharmaceutic...-0.03-0.73%
KERXKeryx Biopharmaceuti...0.000.00%
EGRXEagle Pharmaceutical...-1.62-3.62%
Data as of 3:59pm ET, 07/29/2016

Financials

Last reporting dateJuly 28, 2016
EPS forecast (this quarter)-$0.18
Annual revenue (last year)$27.8M
Annual profit (last year)-$17.6M
Net profit margin-63.37%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Bassil I. Dahiyat
Vice President-Finance &
Investor Relations
John J. Kuch
Corporate headquarters
Monrovia, California

Forecasts

Partner Offers

Search for Jobs